Daily inhaler tested to halt genetic lung disease progression
Disease control
Recruiting now
This study is testing whether inhaling a protein called Alpha-1 Antitrypsin (AAT) daily can slow down worsening lung function in people with a genetic condition called Alpha-1 Antitrypsin Deficiency. For the first two years, 220 participants will either receive the active inhaled…
Phase: PHASE3 • Sponsor: Kamada, Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC